Plant Lectin, MoMo30, Pressures HIV-1 to Select for Variants with Deleted N-Linked Glycosylation Sites

Morgan I Coleman1, Mahfuz B Khan1, Erick Gbodossou2

  • 1Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlannta, GA 30310, USA.

Viruses
|July 30, 2025
PubMed

Insights

The plant protein MoMo30, an anti-HIV agent, induces detrimental mutations in the HIV-1 envelope gene upon prolonged exposure. This genetic pressure reduces viral infectivity, suggesting a novel therapeutic strategy against HIV.

Area of Science:

  • Virology
  • Molecular Biology
  • Drug Discovery

Background:

  • Momordica balsamina contains MoMo30, a protein identified as an anti-HIV entry inhibitor.
  • MoMo30 binds to glycan residues on the HIV-1 gp120 envelope protein.

Purpose of the Study:

  • To investigate if prolonged exposure to MoMo30 induces selective pressure on HIV-1.
  • To determine if MoMo30 causes mutations in the HIV-1 envelope (env) gene.

Main Methods:

  • T-lymphocytes infected with HIV-1 NL4-3 were continuously treated with MoMo30 for 24 days.
  • Viral RNA env genes were sequenced using Illumina, with variant calling via iVar.
  • HIV infectivity was assessed using MAGI-CXCR4 cells and compared to controls.

Main Results:

  • MoMo30-treated HIV-1 developed detrimental mutations in gp120 and gp41, including deletions in N-linked glycosylation sites.
  • 32% of N-linked glycosylation sites were deleted in the treated virus.
  • The MoMo30-treated virus showed a sixfold reduction in infectivity compared to controls.

Conclusions:

  • MoMo30 exerts genetic pressure on HIV-1 NL4-3.
  • This pressure selects for mutations that decrease viral fitness and infectivity.
  • MoMo30 demonstrates potential as a therapeutic agent by compromising viral integrity.